Bridging ED to Outpatient AUD Therapy With Naltrexone
Status:
Not yet recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
Alcohol use disorder (AUD) is a treatable and common condition encountered in the emergency
department, but unfortunately is rarely directly addressed in emergency departments
nationwide. To our knowledge, initiation of medication assisted therapy (MAT) for AUD in the
emergency department setting has not been widely adopted. Our project is novel for its scope
to use a medication well-tested in the outpatient environment and bring it to the emergency
department in order to more effectively link patients to outpatient alcohol use reduction
therapy as part of a medication assisted therapy (MAT). The investigators are proposing a
feasibility project to initiate oral naltrexone to eligible ED patients deemed to have
alcohol use disorder and who are interested in cutting down their drinking. The investigators
plan to connect these patients with outpatient follow-up in our own community practice center
(CPC) for intramuscular (IM) Vivitrol injections under the supervision of the Einstein
Toxicology Department. Through the CPC, patients can also be referred to other supporting
services such as Alcoholics Anonymous for multidisciplinary care. The investigators are
optimistic that this innovative warm hand off from the initial ED visit to outpatient
follow-up will ultimately decrease problematic drinking, improve patient's health, and
benefit the hospital.
Our main objective is to establish a pathway to encourage patients who present to the
emergency room with acute sequelae of alcohol use disorder to enter outpatient treatment. Our
intervention will be the initiation of oral naltrexone with warm handoff to the Community
Practice Center where patients will be transitioned to intramuscular (IM) Vivitrol for
chronic maintenance therapy. Thus success will be measured by primarily: percentage of
patients who make it to their first outpatient visit for the Vivitrol injection, percentage
of patients who continue with treatment and continue to receive Vivitrol for their second
injection.